The termination removes near-term dilution overhang, which is a modest positive for existing holders. However, MAIA is a pre-revenue biotech that relied on ATM for cash — watch for alternative financing announcements (private placement, partnership, or debt) within the next 2-4 weeks. If no new financing appears, cash runway concerns could re-emerge.
Price Chart
Executive Summary
MAIA Biotechnology terminated its at-the-market (ATM) offering agreement with H.C. Wainwright & Co., effective seven business days after May 14, 2026. Since the March 2025 prospectus supplement, the company had sold ~3.1M shares for ~$5.7M in gross proceeds. Termination of the ATM removes a source of future equity dilution but also cuts off a key financing channel for a clinical-stage biotech with a $78M market cap.
Key Facts
- MAIA terminated its ATM sales agreement with H.C. Wainwright & Co., effective ~May 22, 2026.
- Since March 28, 2025, MAIA sold 3,116,012 shares for gross proceeds of approximately $5,680,924 under the ATM.
- The ATM had capacity for up to $11,200,000; approximately $5.5M remained unused at termination.
- MAIA is a clinical-stage biotech with a $78M market cap and no approved products.
Financial Impact
Removes ~$5.5M of potential future equity financing capacity; past ATM raised ~$5.7M in gross proceeds over ~14 months.
Risk Factors
- Loss of ATM removes a flexible financing tool; may force more dilutive or restrictive financing alternatives.
- If MAIA needs capital for clinical trials, it must now seek alternative sources, potentially at worse terms.
- No new financing within 30 days could pressure the stock as cash runway concerns grow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023168 |
| Document: 0001493152-26-023168-index-headers.html | 0001493152-26-023168 |
| Document: 0001493152-26-023168-index.html | 0001493152-26-023168 |
| Document: 0001493152-26-023168.txt | 0001493152-26-023168 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.17 (+0.85%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.17 (−1.68%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.17 (+0.85%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.17 (−16.43%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.17 (−12.69%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.17 (−12.69%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.17 (−18.18%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.17 (−13.33%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.17 (−4.88%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.17 (−7.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers